Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 276.11M P/E - EPS this Y 63.20% Ern Qtrly Grth -
Income 17.63M Forward P/E -3.95 EPS next Y -123.80% 50D Avg Chg -12.00%
Sales 563k PEG - EPS past 5Y - 200D Avg Chg 21.00%
Dividend N/A Price/Book 4.11 EPS next 5Y - 52W High Chg -32.00%
Recommedations 2.00 Quick Ratio 5.87 Shares Outstanding 168.50M 52W Low Chg 168.00%
Insider Own 1.15% ROA -40.23% Shares Float 128.44M Beta 0.36
Inst Own 66.33% ROE 21.77% Shares Shorted/Prior 13.62M/15.37M Price 1.74
Gross Margin 52.40% Profit Margin 3,131.79% Avg. Volume 3,643,658 Target Price 4.05
Oper. Margin -6,020.78% Earnings Date Nov 7 Volume 1,671,654 Change 0.00%
About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals, Inc. News
10/01/24 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/18/24 X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a favorite amongst institutional investors who own 51%
08/28/24 X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
08/13/24 XFOR: First Commercial Sales of XOLREMDI™…
08/08/24 X4 Pharmaceuticals: Q2 Earnings Snapshot
08/08/24 X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
07/30/24 X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
07/08/24 XFOR: Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia Patients…
06/27/24 X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
05/29/24 X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
05/13/24 X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
05/09/24 X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
05/08/24 X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript
05/08/24 XFOR: Data from Phase 2 CN Trial Expected in June 2024…
05/08/24 X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
05/07/24 X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
04/30/24 X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
04/30/24 XFOR: XOLREMDI™ Approved by FDA…
04/29/24 UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
04/29/24 X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
XFOR Chatroom

User Image Universaal Posted - 31 minutes ago

$XFOR remember one big green candle brings 4 greens , today is the first one. See this.70s by eow

User Image 30DeltaSpy Posted - 2 hours ago

$XFOR bullish

User Image SetNForget777 Posted - 3 hours ago

$XFOR

User Image Universaal Posted - 6 hours ago

$XFOR not sure what’s holding not to buy way undervalued stock. FREE MONEY

User Image Universaal Posted - 21 hours ago

$XFOR

User Image Universaal Posted - 1 day ago

$XFOR

User Image justiceforb_85 Posted - 1 day ago

$XFOR mavorixafor costs about $500,000 per year. with upcoming phase 3 data for mavorixafor in congenital neutropenia, if we go with a low estimate of 350 patients, that means $175 million per year from medication sales. The current market cap is less than $100 million. This appears to be undervalued currently. What is the consensus?

User Image LDT79 Posted - 3 days ago

$XFOR tax loss selling season it’s the only explanation - stock is oversold all over the chart yet people still sell

User Image LDT79 Posted - 3 days ago

$XFOR how is it possible that with 60% of tutes ownership this is trading at all time lows with over $100M in the bank !! Mind blowing, for real - people will wait to buy when it is over $1 - sad reality

User Image prodigy81 Posted - 3 days ago

$XFOR $0.5000 is huge wall. We will see how to hold this wall for a while.

User Image LDT79 Posted - 3 days ago

$XFOR This company reported $207M cash first half 2024 - their burn rate is $20 / quarter. They have money until 2026 - one FDA approved drug + another drug in P3

User Image LDT79 Posted - 3 days ago

$XFOR oversold !

User Image LDT79 Posted - 3 days ago

$XFOR 20% down in a week on no news and ahead of Nov P2 data trading below cash - see you in December

User Image LDT79 Posted - 3 days ago

$XFOR it’s going to turn on a dime - $XBI is being shorted last 4 years - US needs a new leadership that goes beyond Trump

User Image KingNeptune Posted - 3 days ago

@Zezo1901 well dang. I thought we had a positive news/data release imminent for $XFOR. Hmmm. Thanks for sharing.

User Image Universaal Posted - 4 days ago

$XFOR cash runaway till 2026

User Image Universaal Posted - 4 days ago

$XFOR

User Image Universaal Posted - 4 days ago

$XFOR data in few days.. insiders had pre-scheduled sell . They must have predicted it would be $2 so the preset sell off was not good.

User Image prodigy81 Posted - 4 days ago

$XFOR Wow...why inside keeps selling stocks with this low price? Aren't they confident about their upcoming drug?

User Image KingNeptune Posted - 5 days ago

$XFOR sad to see the drop but will be happy with the double digits green days ahead.

User Image insiderbuyingselling Posted - 5 days ago

$XFOR new insider selling: 239436 shares. http://insiderbuyingselling.com/?t=XFOR

User Image insiderbuyingselling Posted - 5 days ago

$XFOR new insider selling: 230645 shares. http://insiderbuyingselling.com/?t=XFOR

User Image Fire_Truck Posted - 6 days ago

$XFOR

User Image Fire_Truck Posted - 6 days ago

$XFOR

User Image TheLearnerEarner Posted - 6 days ago

$XFOR ✅ BARGAIN QUALITY stock swing trade - healthcare - small cap - 4/9 F-Score - 1.9x relative volume - 1x analysts outperform rating - 5x analysts buy rating - became profitable this year - revenue is forecast to grow 54.81% per year - trading at 96.7% below our estimate of its fair value - short to medium term gains 📈 RSI: 31.51 (oversold bullish) 📊🐂 Analyst Price Target: $4.05 - $5.25 (666.03% - 859.43% above Price) 🌟 Range (12m) $0.51 - $1.60 💰 NEWSDESK (article idea is for XFOR only) 📰 https://finance.yahoo.com/news/x4-pharmaceuticals-inc-nasdaq-xfor-145901998.html

User Image Gunnar1 Posted - 6 days ago

$XFOR Reentered today with a starter.

User Image Sir_Falstaff Posted - 6 days ago

$XFOR stop the FUD. Do research before posting.

User Image manutd123 Posted - 1 week ago

$XFOR tempting to buy, but RS could be any day now as stock been under $1 for a long while. Thoughts ?

User Image Toodof1345 Posted - 1 week ago

$XFOR any reason for the drop today?

User Image LDT79 Posted - 1 week ago

$XFOR dodged a bullet

Analyst Ratings
HC Wainwright & Co. Buy Jun 28, 24
Cantor Fitzgerald Overweight May 31, 24
HC Wainwright & Co. Buy Apr 30, 24
HC Wainwright & Co. Buy Mar 22, 24
B. Riley Securities Neutral Dec 12, 23
HC Wainwright & Co. Buy Aug 11, 23
Stifel Buy May 17, 23
HC Wainwright & Co. Buy May 5, 23
B. Riley Securities Buy Apr 10, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Ragan Paula President and CEO President and CEO Nov 01 Sell 0.82 239,437 196,338 836,441 11/03/23
WYZGA MICHAEL S Director Director Aug 18 Buy 1.195 25,000 29,875 76,667 08/22/23
Stewart Murray Interim Chief Medica.. Interim Chief Medical Officer Aug 09 Sell 1.06 130,056 137,859 146,504 08/11/23
Ragan Paula President and CEO President and CEO May 31 Sell 1.95 6,292 12,269 557,245 05/31/23
Ragan Paula President and CEO President and CEO Jun 03 Sell 1.21 6,292 7,613 661,806 06/06/22